SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Zosano Pharma Corp (CIK 0001587221) — Jul 12, 2021

Zosano Pharma Corp (CIK 0001587221)
Date: July 12, 2021 · CIK: 0001587221 · Accession: 0001193125-21-212946

AI Filing Summary & Sentiment

File numbers found in text: 333-257682

Date
July 12, 2021
Author
Zosano Pharma Corporation
Form
CORRESP
Company
Zosano Pharma Corp (CIK 0001587221)

Letter

Zosano Pharma Corporation

34790 Ardentech Court

Fremont, CA 94555

July 12, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

Re: Zosano Pharma Corporation

Registration Statement on Form S-3 (Registration No. 333-257682)

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the U.S. Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Zosano Pharma Corporation (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on July 14, 2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Richard Kim at (650) 470-4980.

Thank you for your assistance in this matter.

Very truly yours,
Zosano Pharma Corporation

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 Zosano Pharma Corporation

34790 Ardentech Court

Fremont, CA 94555

 July 12, 2021

VIA EDGAR

 U.S. Securities and Exchange Commission

 Division of Corporation Finance

 Office of Life Sciences

 100 F Street, N.E.

 Washington, DC 20549

Re:
 Zosano Pharma Corporation

Registration Statement on Form S-3 (Registration
No. 333-257682)

 Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby
request acceleration by the U.S. Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the
“Registration Statement”) of Zosano Pharma Corporation (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on July 14,
2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Richard Kim at (650)
470-4980.

 Thank you for your assistance in this matter.

Very truly yours,

Zosano Pharma Corporation

By:

 /s/ Steven Lo

Steven Lo

Chief Executive Officer and President

 [Signature Page to Zosano Pharma Corporation Acceleration Letter]